Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1980 2
1981 1
1982 6
1983 4
1985 4
1986 3
1987 5
1988 6
1989 6
1990 5
1991 9
1992 9
1993 13
1994 11
1995 8
1996 17
1997 33
1998 29
1999 31
2000 35
2001 50
2002 57
2003 79
2004 87
2005 126
2006 128
2007 139
2008 178
2009 204
2010 278
2011 287
2012 353
2013 442
2014 498
2015 579
2016 575
2017 699
2018 718
2019 811
2020 1028
2021 1110
2022 822
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

8,502 results
Results by year
Filters applied: . Clear all
Page 1
AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations.
Lu S, Dong X, Jian H, Chen J, Chen G, Sun Y, Ji Y, Wang Z, Shi J, Lu J, Chen S, Lv D, Zhang G, Liu C, Li J, Yu X, Lin Z, Yu Z, Wang Z, Cui J, Xu X, Fang J, Feng J, Xu Z, Ma R, Hu J, Yang N, Zhou X, Wu X, Hu C, Zhang Z, Lu Y, Hu Y, Jiang L, Wang Q, Guo R, Zhou J, Li B, Hu C, Tong W, Zhang H, Ma L, Chen Y, Jie Z, Yao Y, Zhang L, Jie W, Li W, Xiong J, Ye X, Duan J, Yang H, Sun M, Sun C, Wei H, Li C, Ali SM, Miller VA, Wu Q. Lu S, et al. Among authors: cui j. J Clin Oncol. 2022 May 17:JCO2102641. doi: 10.1200/JCO.21.02641. Online ahead of print. J Clin Oncol. 2022. PMID: 35580297
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study.
Shi Y, Chen G, Wang X, Liu Y, Wu L, Hao Y, Liu C, Zhu S, Zhang X, Li Y, Liu J, Cao L, Cheng Y, Zhao H, Zhang S, Zang A, Cui J, Feng J, Yang N, Liu F, Jiang Y, Gu C; FURLONG investigators. Shi Y, et al. Among authors: cui j. Lancet Respir Med. 2022 Jun 2:S2213-2600(22)00168-0. doi: 10.1016/S2213-2600(22)00168-0. Online ahead of print. Lancet Respir Med. 2022. PMID: 35662408
Editorial: Enzyme Biocatalysts: Design and Application.
Cui J, Zheng GW, Black G, Iqbal HMN, Bilal M. Cui J, et al. Front Chem. 2022 Feb 2;10:851857. doi: 10.3389/fchem.2022.851857. eCollection 2022. Front Chem. 2022. PMID: 35186889 Free PMC article. No abstract available.
Metal Ion-Directed Functional Metal-Phenolic Materials.
Geng H, Zhong QZ, Li J, Lin Z, Cui J, Caruso F, Hao J. Geng H, et al. Among authors: cui j. Chem Rev. 2022 Jul 13;122(13):11432-11473. doi: 10.1021/acs.chemrev.1c01042. Epub 2022 May 10. Chem Rev. 2022. PMID: 35537069 Review.
COVID-19 impact on mental health.
Cui J, Lu J, Weng Y, Yi GY, He W. Cui J, et al. BMC Med Res Methodol. 2022 Jan 14;22(1):15. doi: 10.1186/s12874-021-01411-w. BMC Med Res Methodol. 2022. PMID: 35026998 Free PMC article.
8,502 results